Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ideaya Biosciences Inc (IDYA)

Ideaya Biosciences Inc (IDYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma PR Newswire - Thu Dec 11, 5:00AM CST

SOUTH SAN FRANCISCO, Calif. , Dec. 11, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full...

IDYA : 34.02 (+1.37%)
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers PR Newswire - Wed Dec 10, 5:00AM CST

SOUTH SAN FRANCISCO, Calif. , Dec. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, announced the submission of an investigational...

IDYA : 34.02 (+1.37%)
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types PR Newswire - Mon Dec 1, 5:00AM CST

SOUTH SAN FRANCISCO, Calif. and SHANGHAI , Dec. 1, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development...

IDYA : 34.02 (+1.37%)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Fri Nov 28, 5:00AM CST

SOUTH SAN FRANCISCO, Calif. , Nov. 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

IDYA : 34.02 (+1.37%)
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events PR Newswire - Mon Nov 24, 5:00AM CST

SOUTH SAN FRANCISCO, Calif. , Nov. 24, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted...

IDYA : 34.02 (+1.37%)
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth Business Wire - Thu Nov 20, 3:15PM CST

Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director

IDYA : 34.02 (+1.37%)
TROW : 104.90 (-0.06%)
EXAS : 101.50 (+0.14%)
ILMN : 134.87 (-1.15%)
TMO : 572.28 (-1.14%)
SERA : 3.51 (+3.24%)
IR : 81.76 (-2.01%)
MTD : 1,393.64 (-1.97%)
QTRX : 7.56 (+0.13%)
LIFE : 1.9000 (+2.70%)
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update PR Newswire - Tue Nov 4, 5:00AM CST

SOUTH SAN FRANCISCO, Calif. , Nov. 4, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial...

IDYA : 34.02 (+1.37%)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Fri Oct 31, 5:00AM CDT

SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

IDYA : 34.02 (+1.37%)
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events PR Newswire - Mon Oct 27, 5:00AM CDT

SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted...

IDYA : 34.02 (+1.37%)
IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025 PR Newswire - Mon Oct 20, 5:30AM CDT

SOUTH SAN FRANCISCO, Calif. , Oct. 20, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today presented positive clinical data from their...

IDYA : 34.02 (+1.37%)

Barchart Exclusives

Inflation Data, AI Earnings and Other Can't Miss Items this Week Barchart - 1 minute ago
Markets enter a critical week still reeling from Friday's sharp selloff in technology and AI stocks following disappointing reactions to Oracle and Broadcom earnings that raised questions about AI infrastructure spending sustainability and return on massive capital investments. Here are 5 things to watch this week in the Market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot